Background: Tuberculosis currently stands as the second leading cause of deaths worldwide due to single  infectious agent after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The current challenges of drug resistance in tuberculosis highlight an urgent need to develop newer anti-mycobacterial compounds. In the present study, we report the serendipitous discovery of a bacterial laboratory contaminant (LC-1) exhibiting a zone of growth inhibition on an agar plate seeded with Mycobacterium tuberculosis.

Results: We utilized microbiological, biochemical and biophysical approaches to characterize LC-1 and anti-mycobacterial compound(s) in its secretome. Based on 16S rRNA sequencing and BIOLOG analysis, LC-1 was identified as Staphylococcus hominis, a human bacterial commensal. Anti-mycobacterial activity was initially found in 30 kDa retentate that was obtained by ultrafiltration of culture filtrate (CF). SDS-PAGE analysis of peak fractions obtained by size exclusion chromatography of 30 kDa retentate confirmed the presence of high molecular weight (≥ 30 kDa) proteins. Peak fraction-1 (F-1) exhibited inhibitory activity against M. bovis BCG, but not against M. smegmatis, E. coli and S. aureus. The active fraction F-1 was inactivated by treatment with Proteinase K and α-chymotrypsin. However, it retained its anti-mycobacterial activity over a wide range of heat and pH treatment. The anti-mycobacterial activity of F-1 was found to be maintained even after a long storage (~12 months) at - 20 °C. Mass spectrometry analysis revealed that the identified peptide masses do not match with any previously known bacteriocins.

Conclusions: The present study highlights the anti-mycobacterial activity of high molecular weight protein(s) present in culture filtrate of LC-1, which may be tested further to target M. tuberculosis. The heat and pH stability of these proteins add to their characteristics as therapeutic proteins and may contribute to their long shelf life. LC-1 being a human commensal can be tested in future for its potential as a probiotic to treat tuberculosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799974PMC
http://dx.doi.org/10.1186/s12934-022-01743-2DOI Listing

Publication Analysis

Top Keywords

anti-mycobacterial activity
20
high molecular
12
molecular weight
12
weight proteins
8
bacterial laboratory
8
laboratory contaminant
8
anti-mycobacterial compounds
8
30 kda retentate
8
culture filtrate
8
anti-mycobacterial
7

Similar Publications

A conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant, trehalose monomycolate.

J Clin Invest

December 2024

Department of Molecular Immunology, Research Institute for Microbial Diseas, Osaka University, Suita, Japan.

Mycobacterium tuberculosis causes human tuberculosis. As mycobacteria are protected by thick lipid cell wall, humans have developed immune responses against diverse mycobacterial lipids. Most of these immunostimulatory lipids are known as adjuvants acting through innate immune receptors, such as C-type lectin receptors.

View Article and Find Full Text PDF
Article Synopsis
  • Ursolic acid (UA) and oleanolic acid (OA) are natural compounds with anti-mycobacterial properties but have poor solubility, limiting their use in treatment.
  • Researchers developed solid lipid microparticles (SLMs) to effectively deliver UA and OA, demonstrating their ability to inhibit both drug-sensitive and multidrug-resistant tuberculosis (Mtb) in lab tests.
  • In mouse models, the delivery of SLMs via inhalation significantly reduced bacterial loads and improved survival rates without causing toxicity, showcasing their potential as a safe and effective treatment option for tuberculosis.
View Article and Find Full Text PDF

Antioxidant: Antimycobacterial and Antibiofilm Activities of Acetone Extract and Subfraction Jacq. ex Willd. Against .

Antibiotics (Basel)

October 2024

Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Private Bag X1106, Sovena 0727, South Africa.

Tuberculosis is a worldwide prevalent and recurring disease that contributes significantly to high mortality rates. This study aimed to investigate the antioxidant, anti-mycobacterial, and antibiofilm activities of acetone crude extract. The crude acetone extract was fractionated using column chromatography and characterized by liquid chromatography-mass spectroscopy (LC-MS).

View Article and Find Full Text PDF
Article Synopsis
  • Mycobacterium tuberculosis is a leading cause of global mortality, and to combat it effectively, improvements in diagnostics, drug regimens, and vaccinations are essential.
  • The study investigates Furamidine, a compound that may enhance autophagy—a defense mechanism against pathogens—by evaluating its effects on tuberculosis bacteria within human cells.
  • Findings demonstrate that Furamidine reduces mycobacterial growth and induces autophagy by affecting intracellular calcium levels and activating specific proteins, suggesting it could be a promising approach to improve TB treatment.
View Article and Find Full Text PDF

A series of Triclosan-based hybrids and their Schiff base derivatives with isoniazid were designed through in silico modeling and synthesized using copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. These compounds were then evaluated against both Mycobacterium tuberculosis (Mtb) and Mycobacterium abscessus (Mab). However, none of the synthesized hybrids exhibited significant growth inhibition, with minimum inhibitory concentration (MIC) values consistently exceeding 100 µg/mL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!